Authors: Giuseppe Salvaggio Alessandro Furlan Francesco Agnello Giuseppe Cabibbo Daniele Marin Lydia Giannitrapani Chiara Genco Massimo Midiri Roberto Lagalla Giuseppe Brancatelli
Publish Date: 2013/12/03
Volume: 119, Issue: 4, Pages: 215-221
Abstract
This study was undertaken to compare response evaluation criteria in solid tumours RECIST 11 and modified RECIST mRECIST in patients with unresectable hepatocellular carcinoma HCC on sorafenib and to describe HCC enhancement changes before and after sorafenib treatmentSeventeen patients 12 men 5 women mean age 69 years age range 58–79 years were included Tumour response was assessed according to RECIST and mRECIST Two readers placed a region of interest ROI within each target lesion on the portion showing enhancement during the arterial phase The lesion attenuation values measured within the ROIs on computed tomography or the signal intensity measured on magnetic resonance imaging during the unenhanced phase hepatic arterial phase and venous phase were recorded Changes in arterial and venous contrast enhancement before and after treatment were compared among the mRECIST groups using Mann–Whitney U testAgreement between mRECIST and RECIST was good Cohen’s k coefficient 0791 Patients with partial response had a greater decrease in arterial enhancement −798 than did patients with stable disease SD −248 p = 0011 or progressive disease PD −329 p = 0034 No statistically significant difference in arterial enhancement variation was found among patients with SD and PD No statistically significant difference in venous enhancement was found among the mRECIST groups
Keywords: